Trial reportPsychotherapy and psychosomatics2026
ConquerFear-HK: A Randomized Controlled Trial of a Metacognition-Based, Manualized Intervention for Fear of Cancer Recurrence among Chinese Cancer Survivors.
Trial report in Psychotherapy and psychosomatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence: a Randomized Controlled Trial
Development and Evaluation of An Innovative Program in Mental Health Promotion
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Fear of cancer recurrence (FCR) is a prominent clinical issue among cancer survivors. This study evaluated the effectiveness of the culturally adapted ConquerFear-HK intervention in reducing FCR among Chinese cancer survivors, compared to standard survivorship care.
methodsThis assessor-masked, two-arm parallel randomized controlled trial, was conducted from June 2021 to February 2024. Cantonese- or Mandarin-speaking Chinese cancer survivors scoring ≥13 on the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) were randomized to either ConquerFear-HK, focusing on attention training, metacognition modification, acceptance, appropriate monitoring behaviour, and goal setting or active control providing standardized, multidisciplinary survivorship care. Primary outcome was changes in FCR assessed by FCRI at prior randomization, immediately post-intervention (T1), 3 months (T2), and 6 months (T3) post-intervention. Intention-to-treat analyses using linear mixed modelling compared outcome changes across time points. This trial was registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> (NCT04568226).
resultsOf the 175/220 (79.5%) participants recruited, 89 were randomized to ConquerFear-HK and 86 to control. Significant greater FCRI reductions were observed in ConquerFear-HK at T1 (mean difference = -10.66; 95% CI:-20.15, -1.16) and T2 (mean difference = -12.00; 95% CI:-21.90, -2.11) vs. the control (g = 0.33-0.36). No significant between-group differences were found at T3.
conclusionConquerFear-HK demonstrates promising short-term (3-month) improvements in FCR among Chinese cancer survivors; however, no sustained benefits were found at 6 months. Possible explanations include the high attrition at 6-month follow-up, a potential early ceiling effect, unconscious therapist bias, or an accelerated adaptation effect in the intervention arm that was achieved later by the control group. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.